Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 282-780-4
CAS number: 84418-68-8
Zinc is essential for growth and
development, neurological function, wound healing and immunocompetence
(SCF, 2003). The main clinical manifestations of zinc deficiency are
growth retardation, delay in sexual maturation or increased
susceptibility to infections (SCF, 2003).
Important in this context is the
maintenance of the physiological zinc homeostasis. Disturbance of this
zinc homeostasis through for example excessive zinc exposure have been
implicated with neurogenerative diseases like Alzheimer’s or Wilson’s
disease undefined (Konoha et al., 2006) or with immunosuppressive
effects (Raqib et al.,2007), but the exact mechanisms have not
been elucidated.There is at this stage no evidence that zinc has any
neurotoxicological or immunotoxicological effects under normal zinc
exposure conditions and at recommended zinc intake levels. Zinc
deficiency, however, adversely affects neurological function and immune
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again